Discounting health effects in pharmacoeconomic evaluations: current controversies.
about
Cost-effectiveness of different human papillomavirus vaccines in SingaporeA health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK.Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1.Points to consider in assessing and appraising predictive genetic tests.Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.Could CT screening for lung cancer ever be cost effective in the United Kingdom?Cost-effectiveness of adjuvant chemotherapy with uracil-tegafur for curatively resected stage III rectal cancer.Cost-effectiveness of varicella vaccination programs: an update of the literature.Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study.Pneumococcal conjugate vaccine: review of cost-effectiveness studies in Australia, North America and Europe.Herpes zoster vaccine: A health economic evaluation for Switzerland.Modeling the impact of genetic screening technologies on healthcare: theoretical model for asthma in children.The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France.Cost-effectiveness simulation of a universal publicly funded sealants application program.Descriptive validity of alternative intertemporal models for health outcomes: an axiomatic test.
P2860
Q33859018-ADBB8B7D-E99A-4BC2-ABD6-454F350D7188Q33894866-CB359599-1285-4422-AD04-DA164E59D601Q35002445-AC6C5DB9-55EB-4337-B77F-8ADCD96EC48BQ35263641-A25046F8-ECB6-4B7E-9618-5913E32EF242Q35558544-7D95E8A5-D042-49D0-BF17-59D1399EFA72Q36537744-4D16AF13-692C-4A40-BAF8-706498A67ACEQ36944056-27548551-B8C8-48BA-AAF8-3CDFF2207A2EQ37229923-F6D67360-7AD0-46E4-93A4-9FDE72D7BF13Q37281725-7D4778BB-071B-4F74-BBFC-897C7433AFDFQ37763127-8020579F-5C15-4AEA-B23E-0566471AB896Q38798312-EDA08729-3293-4982-A38D-CBDF018408A7Q40160174-7A74259F-8DAA-4FC1-BFA8-520D97CF9468Q42755023-E5013EF5-3260-4258-AF69-231F586DC9F9Q44931333-5BD0D59A-7208-4767-AA45-E25098F20C66Q51750210-40250C33-3793-4069-ADF6-93C62F08F56AQ51767484-52EBAEEB-0DDF-4867-B576-ADC5D1E6C003
P2860
Discounting health effects in pharmacoeconomic evaluations: current controversies.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Discounting health effects in pharmacoeconomic evaluations: current controversies.
@ast
Discounting health effects in pharmacoeconomic evaluations: current controversies.
@en
type
label
Discounting health effects in pharmacoeconomic evaluations: current controversies.
@ast
Discounting health effects in pharmacoeconomic evaluations: current controversies.
@en
prefLabel
Discounting health effects in pharmacoeconomic evaluations: current controversies.
@ast
Discounting health effects in pharmacoeconomic evaluations: current controversies.
@en
P2093
P1433
P1476
Discounting health effects in pharmacoeconomic evaluations: current controversies.
@en
P2093
Lieven Annemans
Maarten J Postma
P304
P356
10.2165/00019053-200523070-00001
P577
2005-01-01T00:00:00Z
P6179
1036246470